PALO ALTO, Calif. - Scilex Holding Company (NASDAQ:SCLX), a firm specializing in non-opioid pain management solutions, has announced that its product GLOPERBA®, an oral liquid anti-gout medication, will be stocked by a leading national pharmacy chain across the United States.
This move comes ahead of the expected launch of GLOPERBA® in the first half of 2024, as the company anticipates demand for the new gout treatment option.
Gout, a form of arthritis characterized by severe pain, affects approximately 9.2 million people in the U.S. With the incidence of gout rising annually, the market for its treatment is projected to reach $2 billion by 2028.
GLOPERBA® is the first and only FDA-approved liquid formulation of colchicine intended for the prevention of gout flares in adults, and it may benefit over 70% of gout patients who have comorbid conditions requiring precise dosage adjustments.
To ensure product availability for its launch, Scilex has increased production and has inventory ready at Cardinal Health (NYSE:CAH), a third-party logistics service provider. The company is also negotiating with additional pharmacy chains to stock GLOPERBA®.
Scilex's CEO, Jaisim Shah, highlighted the significance of GLOPERBA® as a non-opioid treatment that aligns with the company’s mission to redefine the role of opioids as a last-resort pain medication.
Scilex Holding Company is known for its portfolio of non-opioid pain management products, including ZTlido® for postherpetic neuralgia pain and ELYXYB® for acute migraine treatment.
The company is also advancing its pipeline with product candidates like SEMDEXA™ (SP-102) for sciatica, SP-103 for chronic neck and low back pain, and SP-104 for fibromyalgia, with clinical trials ongoing or slated to commence in 2024.
This strategic initiative to stock GLOPERBA® reflects Scilex's commitment to addressing unmet medical needs in the pain management space. The information in this article is based on a press release statement from Scilex Holding Company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.